Why is Ultragenyx’s FDA gene therapy approval seen as an mRNA readthrough?

The article says STAT framed the Ultragenyx FDA gene therapy approval alongside a Regeneron ultra-rare disease approval as a “validating win for mRNA research.” Its angle is that the significance goes beyond one product, signaling broader regulatory openness to specialized genetic and molecular therapies in rare disease.